DICOTnews October 2025
Last week, we reached an important milestone by presenting the phase 2a results for LIB-01, which show a clear dose-response relationship, good tolerability, and a treatment concept that differentiates itself from current medications. After an initial 3-day dosing period, LIB-01 demonstrated an effect on erectile function lasting eight weeks.
A more in-depth analysis of the results is now underway and will form the basis for the continued planning of a phase 2b study.
Elin Trampe, CEO, Dicot Pharma
Phase 2a Results That Move Us Forward
The main purpose of a phase 2a study is to gather information to optimize the continued development of a drug. We have achieved this – watch our presentation for a more detailed review.
Phase 2b Preparations
Preparations for Phase 2b are underway, including an IND application to the FDA. We have also developed a tablet formulation to be used in the upcoming study, which is planned to start in 2026.
Q3 Reporting
As usual, available both in written form and through a studio-recorded presentation and interview at Direkt Studios.
Longevity Report Highlights LIB-01
In September, global investment bank Oppenheimer released a report on longevity, where erectile health is considered to play an important role, and LIB-01 is highlighted as particularly promising for the future.
Presentation to U.S. Investors
Shortly after the report release, we presented Dicot Pharma at a company showcase organized by Oppenheimer, where the company was introduced to American investors.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.